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Regulation of Cathepsin e gene 
expression by the transcription 
factor Kaiso in MRL/lpr mice 
derived CD4+ t cells
sumie Hiramatsu, Katsue s Watanabe, sonia Zeggar, Yosuke Asano  , Yoshia Miyawaki  , 
Yuriko Yamamura, eri Katsuyama, takayuki Katsuyama, Haruki Watanabe  , Mariko takano-
Narazaki, Yoshinori Matsumoto, tomoko Kawabata  , Ken-ei sada  & Jun Wada  
Global DNA hypomethylation in CD4+ cells in systemic lupus erythematosus (sLe) was suggested 
to play a key role in the pathogenesis. to identify new methylation-sensitive genes, we integrated 
genome-wide DNA methylation and mRNA profiling data in CD4+ cells of MRL/lpr (MRL) and C57BL6/J 
(B6) mice. We identified Cathepsin E (Ctse), in which 13 methyl-CpGs within 583 bp region of intron 1 
were hypomethylated, and Ctse mRNA upregulated in MRL compared with B6 mice. One of methyl-
CpGs, mCGCG was 93.3 ± 2.05% methylated in B6 mice, while 80.0 ± 6.2% methylated and mutated to 
CGGG in MRL mice. Kaiso is known to bind to mCGCG and we hypothesized that it represses expression 
of Ctse in B6 mice. The binding of Kaiso to mCGCG site in B6 mice was reduced in MRL mice revealed 
by ChIP-PCR. EL4 cells treated with 5-azaC and/or Trichostatin A showed the suppression of binding of 
Kaiso to mCGCG motif by ChIp-pCR and the overexpression of Ctse was demonstrated by qpCR. Ctse 
gene silencing by siRNA in EL4 cells resulted in reduction of IL-10 secretion. The hypomethylation of 
mCGCG motif, reduced recruitment of Kaiso, and increased expression of Ctse and Il-10 in CD4+ cells 
may be involved in the pathogenesis of sLe.
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease provoked by aberrant immune responses 
directed against cells and tissues, resulting in inflammation and organ damage1. Five-year survival in patients 
with SLE has improved from 50% in the 1950 s to over 90% currently2. However, the early diagnosis of the disease 
is still challenging and the mortality remains high compared with the general population. Although genome-wide 
association studies (GWAS) have supported the importance of genetic background for development of SLE3, 
incomplete concordance in monozygotic twins who carry the same SLE-susceptibility genes suggests that envi-
ronmental and epigenetic factors are also important for its pathogenesis4. Epigenetic processes refer to heritable 
modifications that regulate gene expression and affect cellular functions without any changes in the genomic 
sequence. DNA methylation, histone modification, and altered miRNA profiling are widely recognized as the 
key epigenetic mechanisms. DNA methylation occurs on the carbon 5 position of the pyrimidine ring of cytosine 
residues from CpG dinucleotides, although it was recently observed to occur on other motifs, CHG or CHH 
(H = A, C, T), in embryonic tissue and induced pluripotent stem cells5. In general, methylation on genomic 
DNA represses gene expression, while demethylation is associated with enhanced transcriptional activities. The 
methylation status is critically involved in the transcriptional regulation by altering the accessibility of several 
transcription factors to the targeted promoters, genome imprinting, and X-chromosome inactivation. The series 
of evidence, such as DNA hypomethylation in SLE CD4+ T cells6, ultraviolet light and drug-induced DNA hypo-
methylation7,8, and association of disease activity with DNA hypomethylation4 suggested the epigenetic mecha-
nisms in the development of lupus. Therefore, study of epigenetic mechanisms may provide important clues how 
environmental factors contribute to the phenotypic expression of autoimmunity related diseases.
We previously demonstrated that hypomethylation of a CpG within cAMP response element (CRE) motif 
links to increased expression of PP2Acα in T cells derived from the patients with SLE9. We also performed global 
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miRNA and mRNA profiling in CD4+ T cells purified from spleen of MRL/lpr lupus-prone mice (MRL) and 
compared with the C57BL/6 (B6) and isolated miR-200a-3p, which is involved in the hypoproduction of IL-2 
in T cells by targeting CtBP2 complex10. To identify the putative methylation-sensitive genes involved in the 
pathogenesis of SLE, we performed the integration analysis of genome-wide DNA methylation and global mRNA 
profiling in CD4+ T cells purified from spleen of MRL and compared with B6 mice. During the screening, we 
have identified cathepsin E (Ctse) gene, in which 13 methyl-CpG-dinucleotides located within 583 bp region 
of intron 1 were hypomethylated, and Ctse mRNA was highly expressed in MRL mice compared with B6 mice. 
One of 13 methyl-CpGs, methyl-CGCG (mCGCG) in B6 mice was hypomethylated as well as mutated to CGGG 
in MRL mice. Kaiso (ZBTB33; zinc finger and BTB domain) is a member of to the BTB (BR-C, ttk, and bab)/
POZ (Pox virus and zinc finger) family, and reported to bind to DNA with dual-specificity in both a sequence- 
(Kaiso-binding site; CTGCNA) and methyl-CpG (mCGCG) specific manner via C2H2 zinc finger (ZF)11 and 
methyl-DNA-binding (MBD) domains12, respectively.
Here, we demonstrate that Kaiso directly binds to mCGCG site in intron 1 of Ctse gene in 
methyl-CpG-dependent manner and represses the transcriptional activity of Ctse in B6 mice, while the demeth-
ylation and mutation of mCGCG to CGGG caused the reduced binding of Kaiso and up-regulated expression of 
Ctse. In immune-mediated cells, Ctse was shown to be involved in processing of antigenic peptides during MHC 
class II-mediated antigen presentation in dendritic cells and macrophages13. In contrast, the role of Ctse in T cells 
in normal physiology and pathobiology in autoimmune diseases remains unexplored. We also found that knock-
down of Ctse gene in cultured EL4 cells resulted in decreased production of IL-10 and that up-regulated expres-
sion of IL-10 was observed in CD4+ T cells isolated from MRL mice compared with B6 mice. IL-10 is known 
to be elevated in the serum and tissues of patients with systemic lupus erythematosus (SLE) and the expression 
of IL-10 is activated by Stat3 (signal transducer and activator of transcription 3) in peripheral CD4+ T cells14. 
Because of its B cell-promoting effects, T cell-derived IL-10 may contribute to autoantibody production and tissue 
damage in SLE. In this communication, we postulate that Ctse represents a new methylation-sensitive gene, like 
previously recognized CD70, CD40L and CD11a15, contributes to the pathogenesis of SLE.
Results
Ctse gene is hypomethylated and upregulated in CD4+ t cells of MRL mice. To identify novel 
methylation-sensitive genes in SLE, we integrated genome-wide DNA methylation and mRNA profiling data in 
splenic CD4+ T cells isolated from MRL and compared with B6 mice. The differentially expressed 188 genes with 
statistical significance revealed by Cuffdiff program were merged with 1,557 enriched regions with significant 
methylation peaks demonstrated by MACS program. The 7 genes were identified and they were associated with 
significant methylation peaks in B6 mice but not in MRL mice (Supplementary Table 1). Since RNA sequence 
data demonstrated most abundant and highly up-regulated expression and of Ctse in splenic CD4+ T cells from 
MRL mice, we next investigated the expression of Ctse in immune-mediated cells. The mRNA and protein levels 
of Ctse prominently were increased in splenic CD4+ T cells from MRL compared with those from B6 (Fig. 1A,B, 
and Supplementary Fig. 1). Although Ctse was shown to be involved in processing of antigenic peptides during 
MHC class II-mediated antigen presentation in macrophages, the expression was prominently up-regulated in 
CD4+ and CD8+ T cells, and B cells in MRL mice, but it is not the case with macrophages (Fig. 1A,B).
In genome-wide DNA methylation analysis, the methylated region expanded 583 bp in intron 1 of Ctse in B6 
mice was identified by MACS program, while it was hypomethylated in MRL mice (Supplementary Table 1 and 
Fig. 1C). Two peaks observed in MRL mice were excluded as duplicate reads by MACS program (Fig. 1C). Next, 
we searched the specific methylated CpGs by bisulphite sequencing in this region. From B6 (n = 1) and MRL 
(n = 1) mice, genomic DNAs were isolated, bisulphite converted, 440 bp region including 13 CpGs in intron 1 
of Ctse amplified by PCR, cloned, and sequenced. As shown in Fig. 1D, 2 CpGs were mutated, while 11 CpGs 
were hypomethylated in MRL compared with B6. We searched candidate transcription factors which bind to 
the 583 bp methylated region in intron 1 through JASPAR database. Kaiso was found and it is known to spe-
cifically recognize the methylated DNA motif (mCGCG) through the C2H2 zinc-finger domains, recruits the 
SMRT (Silencing Mediator of Retinoic acid and Thyroid hormone receptors)/N-CoR (Nuclear hormone receptor 
Co-Repressor)/HDAC3 (Histone deacetylase 3) complex, leading to suppression of its target gene16 (Fig. 1E). 
Indeed, mCGCG motif at 11th CpG site (Fig. 1D, boxed) demonstrated to be mutated to CGGG and 21.7% reduc-
tion of DNA methylation in MRL (76.9%) compared to B6 mice (98.6%). Furthermore, bisulphite converted 
genomic DNAs from B6 (n = 5) and MRL (n = 5) were sequenced to confirm the difference of DNA methyla-
tion pattern between B6 and MRL. The 11th CpG was hypomethyalted in MRL (80.0 ± 6.2%) compared with B6 
(93.3 ± 2.05%) (p = 3.82 × 10−5) (Fig. 1D).
the binding of Kaiso to mCGCG was reduced by hypomethylation. To determine the impacts of 
hypomethylation of mCGCG motif on the transcriptional regulation of Ctse, we induced DNA hypomethylation 
in EL4 cells using well-known DNA methylation inhibitor, 5-azaC. The genomic DNA was purified from EL4 
cells treated with or without 1 μM of 5-azaC for 48 hours and incubated with the methylation-sensitive restric-
tion enzyme AccII, which digests only unmethylated CGCG motifs. By the treatment of 5-azaC, the intensity of 
PCR products derived from AccII-resistant mCGCG was reduced, while those from AccII-sensitive unmethyl-
ated CGCG unaltered (Fig. 2A, Supplementary Fig. 1). Next, EL4 cells were treated with 5-azaC and/or histone 
deacetylase (HDAC) inhibitor, Trichostatin A (TSA). The levels of Ctse mRNA expression were up-regulated 
under the treatment of 5-azaC or TSA in EL4 cells and we also observed the additive effects under simultaneous 
treatment of 5-azaC and TSA (Fig. 2B). Since TSA inhibits HDACs 1, 3, 4, 6, and 10, and it is not specific only 
for HDAC3, we next performed ChIP-qPCR to check the binding of Kaiso and HDAC3 to CGCG motif in EL4 
cells. Under the treatment of 5-azaC and TSA in EL4 cells, ChIP-qPCR demonstrated that the bindings of Kaiso 
and HDAC3 to the hypomethylated CGCG motif seemed to be reduced without statistical differences (Fig. 2C, 
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Figure 1. The expression and methylation status of Ctse gene in CD4+ T cells isolated from MRL/lpr 
lupus-prone (MRL) and C57BL/6 (B6) mice. (A) mRNA expression of Ctse in CD4+, CD8+, B cells and 
macrophages in B6 and MRL mice. ***p < 0.001. (B) Western blot analyses of CTSE in CD4+, CD8+, B cells 
and macrophages in B6, MRL and mice. (C) Methylated region expanding 583 bp in Ctse intron 1 in B6 mice 
demonstrated by UCSC Genome Browser. In MRL mice, 583 bp region is hypomethylated. Duplicate reads 
are indicated by arrows. (D) Nucleotide sequence within 583 bp flanking region of Ctse intron 1 in B6 mice. 
Among 13 CpGs (red and underlined), 11th CpG (boxed) includes mCGCG binding motif for Kaiso. After 
genomic DNAs were bisulphite converted, amplified by PCR using Primer F1 and R1, subcloned, and isolated 
clones sequenced. 98.6% of CpGs (71 out of 72 colonies) in B6 mice and 76.9% CpGs (50 of 65) in MRL mice 
were methylated. (E) The structure of Kaiso, SMRT (Silencing Mediator of Retinoic acid and Thyroid hormone 
receptors)/N-CoR (Nuclear hormone receptor Co-Repressor), and HDAC3 (Histone deacetylase 3) complex. 
BTB (for BR-C, ttk and bab), POZ (for Pox virus and Zinc finger) and C2H2 zinc-finger domains are shown. (F) 
DNA sequencing of bisulphite converted DNAs in Ctse intron 1 in B6 and MRL mice. Percentage of methylation 
of 11th CpG is shown (n = 5). ***p < 0.001.
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Supplementary Fig. 1). Since the treatment of EL4 cells with 5-azaC results in global hypomethylation, we can-
not negate the possibility that the increase in Ctse expression is caused by hypomethylation of other regions of 
genomic DNA. Thus, we next compared AccII-resistant mCGCG and AccII-sensitive unmethylated CGCG in 
CD4+ T cells derived from B6 and MRL mice. The ratio of AccII-resistant mCGCG was reduced in MRL mice 
(Fig. 2A). In addition, the bindings of Kaiso and HDAC3 to the Ctse intron 1 in CD4+ T cells of MRL and B6 
mice. ChIP-qPCR revealed that Kaiso and HDAC3 bindings to the Ctse intron 1 were reduced in MRL CD4+ T 
cells compared with B6 CD4+ T cells (Fig. 2D, Supplementary Fig. 1).
Binding of Kaiso to Kaiso regulatory region of Ctse gene. To demonstrate the binding of Kaiso to 
Kaiso regulatory region of Ctse gene, we incubated nuclear proteins from EL-4 cells with labeled double-stranded 
oligonucleotides containing the CGCG motif (Supplementary Table 2). In EMSA (Fig. 3A), the biotin-labeled 
methylated wild type probe (B6-Me; mCGCG) formed DNA-protein complex (asterisk), which were supershifted 
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Figure 2. Kaiso binding to mCGCG motif located in Ctse intron 1 and HDAC3 (Histone deacetylase 3) in 
CD4+ T cells from MRL mice. (A) Methylation specific PCR analysis in EL4 cells treated with or without 1 μM 
of 5-azaC, and CD4+ T cells derived from B6 and MRL mice. Methylation-sensitive restriction enzyme AccII 
digests unmethylated CGCG motifs, while methylated CGCG is resistant to AccII. The genomic DNAs were 
digested with AccII, amplified by PCR using primer sets; Primer F2/R2 and Primer F2/R3. The densitometry 
intensity ratios of PCR products (F2R2/F2R3) are shown. *p < 0.05. (B) mRNA expression of Ctse in EL4 cells 
treated with 1 μM of 5-azacytidine (5-azaC) and/or 100 nM of Trichostatin A (TSA). *p < 0.05, **p < 0.01, 
***p < 0.001. (C) DNA binding of Kaiso and HDAC3 around mCGCG motif located in Ctse intron 1 
examined using ChIP-PCR in EL4 cells. EL4 cells treated with 1 μM of 5-azacytidine (5-azaC) and/or 30 nM of 
Trichostatin A (TSA). ChIP-PCR was performed in 3 independent culture experiments. **p < 0.01. (D) DNA 
binding of Kaiso and HDAC3 around mCGCG motif in CD4+ T cells isolated from B6 and MRL mice. The 
amount of precipitated DNAs was quantified using real-time PCR with primers specific to 583 bp region in Ctse 
intron 1. ChIP-PCR was performed in 3 independent animals. *p < 0.05.
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by anti-Kaiso antibody (arrow head), and disappeared by cold competitor (B6-ME). Anti-HDAC3 antibody failed 
to demonstrate the supershift. The incubation of biotin-labeled MRL-Me (mCGGG) or MRL (CGGG) probes 
with nuclear extracts demonstrated the presence of DNA-protein complexes (asterisks) and they were disap-
peared by cold competitor (B6-Me), which efficiently binds to Kaiso. However, they were not efficiently super-
shifted by anti-Kaiso and anti-HDAC3 antibodies (Fig. 3B), suggesting reduction of the binding of Kaiso to the 
Kaiso regulatory region of Ctse gene in MRL mice.
Kaiso regulates the Ctse promoter activity. To demonstrate transcriptional repression activity of 
Kaiso, we subcloned the Kaiso regulatory region with CGCG motif and PU.1 promoter region with PU.1 bind-
ing site into pGL4.10 [luc2] Vector. PU.1 promoter region was known to display the most potent promoter 
activity of Ctse17. The various constructs are shown in Fig. 4A and Supplementary Fig. 2. pGL4.10-MRL/MRL 
construct demonstrated the highest luciferase activity, while pGL4.10-B6/B6 construct revealed significantly 
lower luciferase activity (Fig. 4B). It suggested that CGCG motif at Kaiso regulatory region is critical for the 
repression of transcriptional activity of Ctse gene. We next investigated the effect of DNA methylation of Kaiso 
regulatory region. The methylation of constructs significantly and prominently repressed luciferase activities in 
pGL4.10-MRL-Me/MRL-Me and pGL4.10-B6-Me/B6-Me constructs compared with corresponding unmethyl-
ated constructs (Fig. 5B). Taken together, Kaiso bind to the mCGCG motif in Kaiso regulatory region and repress 
its transcriptional activity.
Ctse knockdown in EL4 cells reduces IL-10 secretion in EL4 cells. The treatment of EL4 cells by 
si-CTSE resulted in the 60% reduction of mRNA expression of Ctse compared with si-Control (negative control) 
treated cells (Fig. 5A). Although the reduction of Ctse did not significantly alter the mRNA expression of Il10 
after the stimulation with PMA/Iono (Fig. 5B), the secretion of IL-10 into the culture media was significantly 
reduced at 24 hours after the stimulation with PMA/Iono (Fig. 5C), suggesting suppressed secretion of IL-10 was 
not caused by the reduction of transcriptional activity of Il10. The viability of EL4 was investigated by Trypan 
Blue and the percentage of live cells are similar in both si-Control and si-CTSE groups (Fig. 5C). The upregula-
tion of Ctse in CD4+ T cells in MRL mice was associated with the upregulation of transcriptional activity of Il10 
(Fig. 5D). The upregulated expression of Il10 under the control of Ctse was specific phenomenon by the treatment 
of si-CTSE and it was down-regulated in CD4+ T cells from MRL mice (Fig. 5B,D). The tumor suppressor, pro-
gramed cell death 4 (Pdcd4), inhibits the translation of Il10 transcripts and the secretion is enhanced in spleno-
cytes in Pdcd4 knockout mice18. As shown in Fig. 5D, mRNA expression of Pdcd4 in CD4+ T cells was higher in 
B6 mice compared to MRL mice, as previously reported19. Taken together, the hypomethylation and mutation 
of a Kaiso-binding site in the Ctse intron 1 prevents the biding of Kaiso-HDAC3 complex, which may link to the 
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Figure 3. The binding of Kaiso on the mCGCG motif of Kaiso regulatory region of Ctse gene. (A) Biotin-
labeled and methylated probe (B6-Me) was incubated with 28 μg of nuclear protein from EL4 cells, and putative 
Kaiso and DNA complexes is indicated by asterisk in lane 2. The formation of Kaiso and DNA complexes was 
inhibited by excess amounts of unlabeled competitor (lane 3). The Kaiso and DNA complexes demonstrated 
supershift by the addition of 4 μg of anti-Kaiso Ab (arrow head in lane 4). (B) Biotin-labeled, unmethylated 
(MRL), and methylated (MRL-Me) probes were incubated with 28 μg of nuclear protein from EL4 cells. The 
putative Kaiso and DNA complexes are indicated by asterisks in lanes 2 and 7 and they reveal no supershift with 
anti-Kaiso Ab and anti-HDAC3 Ab.
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increased histone acetylation, upregulated mRNA expression of Ctse gene, and enhanced secretion of IL-10 from 
CD4+ T cells in MRL mice (Supplementary Fig. 3).
CTSE and IL10 mRNA were elevated in CD4+ t cells from the patients with sLe. We investi-
gated the expression levels of CTSE and IL10 mRNAs in circulating CD4+ T cells isolated from SLE patients and 
healthy subjects. The demographics of enrolled SLE patients are shown in Supplementary Table 3. SLE patients 
also showed the similar tendency with MRL mice; the expression level of Ctse and IL10 mRNAs in CD4+ T cells 
is upregulated in lupus patients than healthy control (Fig. 6A,B), while PDCD4 mRNA lower tendency in lupus 
patients than healthy control (Fig. 6C). However, there was no significant correlation between Ctse and IL10 
mRNA expression levels (Fig. 6D). Although we searched the correlation with clinical parameters appeared in 
Supplementary Table 3, we failed to demonstrate the correlation of Ctse and IL10 mRNA expression levels with 
any clinical parameters.
Discussion
Methylation of target sequences prevents the binding of certain transcriptional activators, such as AP-2, thereby 
suppressing gene expression20. Methyl-CpG-binding proteins (MBPs) are able to prevent the binding of transcrip-
tion factors and suppress gene expression from a distance21, and it also attracts chromatin remodeling complexes 
that modify adjacent histones, resulting in a condensed nucleosome structure, making the locus inaccessible 
to transcription factors22. Methylated DNA can be recognized by MBPs, which belong to three different struc-
tural families in mammals: the MBD family, Kaiso-like proteins, and the SRA (SET and RING finger associ-
ated domain) proteins23. They are involved in many biological and pathological processes, including control of 
genome stability, early embryonic development, neuron maturation, and T cell differentiation, as well as human 
diseases such as Rett syndrome and cancer24. The transcription factors which regulate the expression of Ctse had 
been reported. Cook et al. reported that the expression of the Ctse gene is probably dependent upon the balance 
between positive-acting, tissue-specific transcription factors such as GATA1 and PU1, and the negative influence 
of the ubiquitous factor YY125. Okamoto et al. identified the several unique transcriptional activators, such as 
Sp1, AP-1 and cEts-1 for the mouse Ctse gene17. In current investigation, we present the first evidence that Ctse as 
a newly identified methylation-sensitive gene, which is involved in the pathogenesis of SLE. Specifically, CD4+ 
T cells from MRL mice demonstrated decreased binding of the transcriptional factor Kaiso to Kaiso regulatory 
motif at intron 1 of Ctse gene because of its lower methylation status and point mutation. Importantly, upregu-
lated Ctse expression level in T cells correlated with the IL-10 expression in EL4 cells and CD4+ cells from MRL 
mice. The upregulation of IL-10 in lupus T cells is well-known14 and Pdcd4, the know suppressor of IL-10 produc-
tion26, is reported to be down-regulated in lupus T cells19. In EL4 cells and CD4+ cells from MRL mice, increased 
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higher luciferase activity compared with pGL4.10-B6/B6 construct (***p < 0.001). DNA methylation of 
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production of IL-10 and reduced expression of Pdcd4 were observed. Although the precise molecular mechanism 
remains unknown, the knockdown of Ctse gene resulted in reduced IL-10 release.
Among various cathepsins, it has been reported that the inhibition of cathepsin S (Ctss) may suppress disease 
activity of SLE and lupus nephritis27. The deficiency of Blimp-1, transcriptional repressor of Ctss, in dendritic 
cells (DCs) led to increased Ctss expression, which resulted in a more diverse repertoire of follicular helper T cell 
(Tfh cell) contributing to autoimmunity in female C57BL/6 mice. A treatment of Blimp-1 knockout mice with 
Ctss inhibitor abolished the lupus-related phenotype and reduced the diversity of the Tfh cell TCR repertoire28. 
The elevated expression of Blimp-1 was induced by IL-12 in a STAT4-dependent manner and IL-10 expression 
in Th1 cell was up-regulated by Blimp-129. The elevated Blimp-1 in SLE patients and in MRL mice positively 
correlated with the increase in plasma cells, autoantibodies and disease activity30. Although the functional role of 
Ctss in SLE is well-investigated, the information about Ctse in the pathogenesis of SLE is scarce. The functional 
roles of Ctse have been reported exclusively in regulatory T (Treg) cells. The elevation of Ctse gene was reported 
in IL-10/IL-35 double-deficient Treg cells, where Ctse enhanced TNF-related apoptosis-inducing ligand (TRAIL) 
expression and release of soluble form31,32, and activated CD4+ Foxp3+ Tregs and CD8+ TTregs utilize TRAIL 
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Figure 5. Expression of Il10 in EL4 cells transfected with siRNA for Ctse and CD4+ T cells isolated from B6 
and MRL mice. (A) The knockdown and mRNA expression of Ctse in EL4 cells transfected with 5 μM control 
siRNA (si-Control) or Ctse siRNA (si-CTSE). *p < 0.05. (B) mRNA expression of Il10 in EL4 cells transfected 
with siRNAs for 24 hours and subsequently stimulated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA) 
and 1 μM Ionomycin for 6 hours. (C) The concentration of IL-10 in supernatants and cell viability of cultured 
EL4 cells. EL4 cells were transfected with indicated siRNAs for 24 hours, stimulated with 10 ng/ml PMA and 
1 μM Ionomycin for 12 or 24 hours. In cell viability, percentage of Trypan Blue negative cells is shown. *p < 0.05, 
***p < 0.001. (D) mRNA expression of Il10 and Pdcd4 in CD4+ T cells isolated from B6 and MRL mice. 
***p < 0.001.
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as suppressive mechanisms by inducing apoptosis, promoting programmed regulated necrosis (necroptosis), and 
inhibiting cell proliferation33 to compensate for loss of IL-10 and IL-3533. Treg cells from Il10 (−/−) mice, which 
fetal loss induced by LPS was at high frequency, were increased in pregnancy and the expression of Ctse, Ifng, and 
Il12rb2 in Treg cells was also enhanced34. 293 T cells which were transfected with expression plasmids encoding 
TRAIL limited T cell proliferation, and was further enhanced in the presence of expression plasmids encoding 
Ctse33. This suggests that Ctse may play a role in enhancing the function of TRAIL by either increasing its activity 
via processing or increasing the generation of soluble TRAIL35. Expression of IL-10 and/or IL-35 by wild-type 
Tregs may suppress Ctse expression and thus reduce the contribution of TRAIL-mediated killing. Chloroquine, 
an anti-malarial drug, which has immune-modulating activity and lysosomotropic activity, enhanced TRAIL 
mediated apoptosis in cancer cells36. SLE patients had significantly greater expression of TRAIL, TNF-like weak 
inducer of apoptosis (TWEAK), and FasL on CD4+ T cells than healthy control, which correlated with disease 
activity37. It has been reported that increased T cell Ctse and subsequent TRAIL expression may exacerbate lupus 
by increasing CD4+ Th cell numbers and inhibiting CD8+ Tcytotoxic T cell-mediated killing of autoreactive B 
cells38 and it may not be a compensatory mechanism to limit lupus activities. In contrast to MRL mice, Tulone, C., 
et al. reported the natural Ctse deficiency in immune system of B6 mice because of a polymorphism of the pro-
motor region of Ctse damped promotor activity of PU.1 binding consensus sequence in B6 mice. The deficiency is 
cell-type-specific, as protein levels in gut are not affected, while the deficiency affects B cell, T cells, macrophages 
and dendritic cells39. The reduction of Ctse expression is largely dependent on the genetic background of B6 mice 
rather than Faslpr mutation.
The role of IL-10 whether it promotes or limits disease activity of SLE remains controversial. Autoimmune 
lymphoproliferative syndrome (ALPS) is an inherited disorder in which genetic defects in proteins that mediate 
lymphocyte apoptosis, most often Fas, are associated with enlargement of lymph nodes and the spleen and a vari-
ety of autoimmune manifestations like MRL mice. ALPS patients have dramatic elevations in circulating IL-10, 
and double negative T cells (DNTC) are the dominant producers of IL-10 when assessed ex vivo40. Although 
immunosuppressive therapy of ALPS patients decreases DNTC and serum IL-10 levels41, the roles of DNTC 
and IL-10 remain unclear. IL-10/Janus kinase/signal transducer and activator of transcription 3 (STAT3) path-
way drives the expression of Bim, anti-apoptotic Bcl-2 family member, in DNTC derived from ALPS patients42. 
The severity of lupus in MRL mice were enhanced by the deletion of Il10 gene. It was associated with enhanced 
IFN-γ production by both CD4+ and CD8+ Tcells and increased serum concentration of IgG2a anti-dsDNA 
autoantibodies43. Administration of rIL-10 reduced IgG2a anti-dsDNA autoantibody production and Th1 
cytokine responses in wild-type MRL-Fas(lpr) in early phase43. Although the beneficial role of IL-10 has been 
reported, anti-IL-10 antibody may have a beneficial effect at later phases of disease, because excessive amounts 
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Figure 6. The increased levels of CTSE and IL10 transcripts in CD4+ T cells from SLE patients. (A) and (B) 
mRNA expression of CTSE and IL10 in CD4+ T cells isolated from healthy (n = 8) and the patients with SLE 
(n = 15). (C) mRNA expression of PDCD4. There is no significant difference in healthy subjects and patients 
with SLE. (D) The simple correlation between the CTSE and IL10 transcript levels. *p < 0.05.
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of IL-10 production may lead to enhanced autoantibody production and subsequent formation of pathogenic 
autoantibody-Ag complexes44.
In addition to IL-10-dependent mechanisms, Ctse plays another key role for the development of SLE. Ctse defi-
ciency caused autophagy impairment concomitantly with increased damaged mitochondria as well as increased 
oxidative stress45. Aberrant autophagy played an important role in the development of SLE46. Gros et al. detected 
more autophagosomes in mice and human lupus T lymphocytes47. Chen, J., et al. found that increased autophagy 
in T cells from SLE patients due to energy “starvation”, excessively accumulated mitochondria and over-activated 
autophagy promoted apoptosis of T cells from SLE patients48. Since the accumulated defective mitochondria 
could not match the high energy consumption within T cells in lupus with high disease activity, they may thus 
induce apoptosis, subsequently increasing autoantibody formation49. Thus, the regulation of energy state of T 
cells could probably be a new treatment target for SLE. Chloroquine, which blocks lysosomal degradation, pre-
vented the contents in autolysosome from recycling and was unable to maintain cellular energy levels. Ctse works 
for lysosomal degradation and relate to mitochondrial function such as intracellular ATP levels, mitochondrial 
membrane potential, and mitochondrial oxygen consumption45. Based on line of evidences, one can suppose 
that overexpression of Ctse may be compensatory mechanism acting to limit lupus severity, Ctse will suppress the 
increased autophagy via elevation of defective mitochondria in lupus.
In conclusion, we presented the evidence that hypomethylation and mutation of the mCGCG site of the Ctse 
intron 1 in MRL mice disrupt the ample binding of Kaiso which results in increased expression of Ctse and Il10 
in SLE T cells. Whether upregulation of Ctse and Il10 is compensation or promoting factors for disease activity of 
SLE remains for future investigation.
Methods
Mice. Genetically lupus-prone female MRL/MpJ-Faslpr/J (MRL) mice, B6.MRL-Faslpr/J mice (B6MRL) 
(Jackson Laboratory), and C57BL/6 J (B6) mice (Charles River Laboratories) were purchased. At 16 weeks of age, 
MRL and B6 mice were sacrificed, and their spleen tissues were collected.
Isolation of mouse primary T cells, B cells and peritoneal macrophages. Mouse splenic CD4+ 
T cells, CD8+ T cells, B cells were isolated using a CD4 isolation kit II (Miltenyi Biotec), CD8a isolation kit II 
(Miltenyi Biotec) and PanBcell isolation kit II (Miltenyi Biotec) by negative selection, respectively. A purity rate 
of >96.6% for isolated CD4+ T cells, CD8+ T cells and B cells were confirmed by flow cytometry. Peritoneal 
macrophages were obtained from B6 and MRL mice by washing their peritoneal cavities with 15 ml of ice-cold 
saline. The cells from individual mice were centrifuged at 1500 rpm for 5 minutes at 4 °C, washed in complete 
DMEM (Life Technologies) supplemented with 10% FBS (Life Technologies), 100 U/ml penicillin, and 100 μg/ml 
streptomycin, and subsequently adjusted to 1 × 107 cells/ml. The cells were cultured on 12-well flat-bottom tissue 
culture plates (Corning) and incubated for 3 hours at 37 °C under 5% CO2 air.
Genome wide DNA methylation and mRNA profiling using a next-generation sequencer. 
Genomic DNAs and total RNAs were purified from CD4+ T cells of MRL mice and B6 mice using All Prep DNA/
RNA Mini Kit (Qiagen). The quality of the DNA was confirmed by fluorometer using Qubit dsDNA BR Assay 
Kits (Invitrogen). EpiXplore Methylated DNA Enrichment Kit (Clontech) was used for enriching methylated 
DNA fragments from the genomic DNA. First, we prewashed TALON Magnetic Beads and couple MBD2 protein 
to magnetic beads, bound methylated DNA to MBD2 protein/magnetic beads complexes, removed non- and 
hypomethylated DNA, eluted, and purified the methylated DNA. Illumina TruSeq ChIP Sample Prep Kit was 
used for the construction of sequencing libraries, and they were subjected to sequencing using Illumina HiSeq. 
The previously published mRNA sequencing data10 appeared in Gene Expression Omnibus (https://www.ncbi.
nlm.nih.gov/geo/) under the accession number GSE87219 was analyzed with Cuffdiff program, and integrated 
with genome wide DNA methylation profiling data (GSE102421). In brief, significant methylation peaks in B6 
and MRL mice were identified with model-based analysis of ChIP-Seq (MACS 1.4.2) using parameters band-
width = 300, mfold = 10,30, and gzise = 187000000050, mapped to genome, differentially methylated regions 
(DRMs) between B6 and MRL mice identified, and duplicate reads removed. The list of genes with read numbers 
of mRNA were merged with annotation of enriched regions. The read depth, enriched regions, mapping informa-
tion was visualized by UCSC Genome Browser.
EL4 cell line culture. The EL4 mouse T cell line was obtained from the American Type Culture Collection 
and cultured in DMEM (Life Technologies) supplemented with 10% FBS (Life Technologies), 100 U/ml peni-
cillin, and 100 μg/ml streptomycin. A total of 4 × 106 cells/ml (EL4 cells or MRL- and B6 mice-derived CD4+ T 
cells) were treated with 1.0 μM 5-azacytidine (5-azaC; Sigma-Aldrich) for 48 hours and with 30 nM Trichostatin 
A (TSA; WAKO) at 37 °C in a 5% CO2 incubator. The concentrations of 5-azaC and TSA were determined by the 
titration by counting Trypan Blue-negative viable cells. The percentages of viable cells were as follows; 5-azaC 
(93.3% at 0 μM, 89.6% at 0.2 μM, 82.9% at 1.0 μM, 0% at 5.0 and 10 μM) and TSA (97.5% at 0 nM, 85.4% at 30 nM, 
49.6% at 300 nM, 44.6% at 1 μM, 38% at 3 μM).
Bisulphite sequencing. Genomic DNA isolated from CD4+ T cells of MRL (n = 5) and B6 (n = 5) mice 
was bisulphite converted using the MethylEasy Xceed Rapid DNA Bisulphite Modification Kit (TaKaRa) fol-
lowing the manufacturer’s protocol. Cytosines are converted to uracils whereas 5-methylcytosines are unreac-
tive. The 440 bp fragment within 583 bp region at intron 1 of Ctse was amplified by nested PCR with EpiTaq 
HS (TaKaRa) and a set of primers: Primer F1: 5′-TAGGTATGTTTTTTATTTATATTTTTAGTG-3′ and Primer 
R1: 5′-GACTAAATAAATTTTCTTTTTCTAATACTT-3′. PCR products were gel purified with NucleoSpinGel 
and PCR clean-up (TaKaRa) kits. DNA direct sequencing was performed with BigDye Terminator v3.1 Cycle 
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Sequencing kit (Thermo Fisher Scientific) and methylation patterns at the level of individual CpG sites were 
examined.
Furthermore, the purified PCR products from CD4+ T cells of MRL (n = 1) and B6 (n = 1) mice were indi-
vidually cloned into a T-vector pD20 using the DNA Ligation Kit Mighty Mix, and transformed to E.coli HST08 
Premium Competent Cells (TaKaRa). The 72 plasmid clones in B6 and 65 in MRL were isolated and sequenced.
Methylation specific pCR. To evaluate the methylation status of the CGCG motif in the Ctse promoter, 
genomic DNA (1 μg) from EL4 cells was purified and treated with EcoRI (TaKaRa) and the methylation-sensitive 
restriction enzyme AccII (New England Biolabs). mCGCG is resistant to AccII digestion, while CGCG is sensitive. After 
DNA re-purification, 50 ng of DNA was used as a template, and Primer F2: 5′-ACGGCTTTTGTGTTTTGGCT-3′ and 
Primer R2: 5′-ACATCAGCACTTAGGTTCTGCT-3′, or Primer R3: 5′-GCCCTGGTTCAATCCCTAAT-3′ were used 
for PCR. PCR products were electrophoresed on 2% agarose gels, visualized by ethidium bromide staining, and quanti-
fied with ImageQuant TL software (GE Health Life Sciences). The PCR products amplified with F2 and R2 corresponds 
to the amount of AccII-resistant DNA, while the products by F2 and R3 reflects total amount of genomic DNAs.
Patients and T lymphocyte purification. The 15 SLE patients (10 females and 5 males) who fulfilled at 
least 4 of the 11 revised criteria of the American College of Rheumatology for the classification of SLE51 enrolled 
and newly developed the disease. The samples were obtained in prior to the treatments with immunosuppressive 
agents and glucocorticoids. The disease activity was assessed by the SLE disease activity index (SLEDAI)52. The 
healthy volunteers were recruited as controls. The current clinical investigation was conducted in accordance 
with the ethical standards laid down in the Helsinki Declaration by the World Medical Association, as well as 
“Ethical Guidelines for Medical and Health Research Involving Human Subjects” presented by the Ministry of 
Health, Labour and Welfare. The studies were approved by the Ethical Committee, Okayama University Hospital 
(#1779). Written informed consents were obtained from all participants. CD4+ T lymphocytes were purified 
using the RosetteSep Human CD4+ TCD4+ T Cell Enrichment Cocktail (Stem Cell Technologies). The samples 
were centrifuged over a buoyant density medium, RosetteSep DM-L. The purified CD4+ TCD4+ T cells were 
recovered from the interface between the plasma and the buoyant density medium. Using flow cytometry, we 
established that the purified cells were >94% positive for CD4. Subsequently, both RNA and DNA were extracted 
from CD4+ T cells using the AllPrep DNA/RNA Mini Kit (Qiagen) according to the manufacturer’s protocol.
RNA isolation and real-time Rt-pCR. Total cellular RNAs from human and mouse samples were 
extracted with an RNeasy mini kit (Qiagen). cDNAs were reverse transcribed from mRNAs with a high-capacity 
cDNA RT kit (Thermo Fisher Scientific). Real-time PCRs for Ctse (Mm00456010_m1), Il10 (Mm01288386_
m1), Il17a (Mm00439618_m1), Pdcd4 (Mm01266062_m1), Gapdh (Mm99999915_g1) for mouse, CTSE 
(Hs00157213_m1), IL10 (Hs00961622_m1), PDCD4 (Hs00377253_m1) and GAPDH (Hs02786624_g1) for 
human were performed using ABI TaqMan gene expression assays (Applied Biosystems) and normalized to 
GAPDH by the ΔΔCt method (Supplementary Table 4).
Western blot analysis. The lysates of murine splenic CD4+ T cells were prepared by homogenization with 
CelLytic M, supplemented with a protease inhibitor cocktail (Sigma-Aldrich). Protein concentration was deter-
mined using the Pierce BCA protein Assay kit (Thermo Fisher Scientific). The samples were run on a 4–20% 
Mini-PROTEIN TGX Precast Gel (Bio-Rad) electrophoresis (SDS-PAGE) and blotted on Amersham Hybond 
P 0.45 µm PVDF (GE Healthcare Life Sciences). Primary antibodies against CTSE at 1:2,000 dilution (NB400-
152, NOVUS) and beta-Actin at 1:1,000 dilution (ab8227; abcam) in 5% bovine serum albumin in TBS supple-
mented with 0.1% Tween 20 (TBS-T) were incubated overnight at 4 °C. Then, the blots were washed with TBS-T 
and incubated with donkey anti-rabbit IgG-HRP (1:5,000; SANTA CRUZ) for 45 minutes at room temperature. 
After three-time washes with TBS-T, bands were visualized with enhanced chemiluminescence using the Pirece 
Western Blotting Substrate Plus (Thermo Fisher Scientific). Protein bands were semiquantified by densitometry 
using ImageQuant TL software (GE Healthcare Life Sciences).
Chromatin immunoprecipitation (ChIp)-qpCR. ChIP-qPCR was performed in accordance with the 
manufacturer’s instructions (Cell Signaling Technology). Briefly, cells were cross-linked with 1% formaldehyde. 
After the cross-linked cells were lysed, the chromatin was harvested and fragmented with enzymatic digestion 
using micrococcal nuclease. Nuclear extracts were further treated with an ultrasound sonicator with three sets of 
20-s pulses. Immunoprecipitations were performed with Kaiso (ab12723; Abcam) and HDAC3 (ab7030; Abcam) 
antibodies. After DNA-protein cross-links were reversed, the DNA was purified, and qPCR was performed with 
Custom Taqman™ Gene Expression Assays (AIQJDG8) by forward primer: 5′-GCCTTCGGTGTGCATGCTA-3′ 
and reverse primer 5′-CACTTAGGTTCTGCTTATGGTAACGT-3, and probe 5′-TTTCCCCGCGAGACTT-3′ 
and all values were standardized with input DNA.
eLIsA. The amount of IL-10 protein secreted in the supernatants from cell cultures was measured by ELISA in 
accordance with the manufacturers’ instructions (mouse IL-10 ELISA Ready-SET-Go!, eBioscience). The absorb-
ance was determined using a microplate reader set at 450 nm.
small Interfering RNAs (siRNAs) transfections. EL4 cells were transfected with 5 μM si-CTSE (Ctse 
Silencer Select Pre designed siRNA ID: s64606 and s64607) or si-Negative-Control (Si-Control) using Neon elec-
troporation system (Thermo Fisher Scientific) in serum-free medium with one pulse with a voltage of 1080 Volts 
and width of 50 ms. Twenty-four hours after transfection, 106 cells/ml were stimulated with 10 ng/ml phorbol 
12-myristate 13-acetate (PMA) and 1 μM Ionomycin (Sigma-Aldrich).
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electrophoretic mobility shift assay (eMsA). Nuclear extracts were prepared from EL4 cells using 
NXTRACT (Sigma-Aldrich). In binding assays of 20 μl total volume, 28 μg of total nuclear extract from EL4 
cells was incubated with 20 fmol of 3′ biotin-labeled oligonucleotide in the presence of 2 μl of 10× binding 
buffer (100 mM Tris, 500 mM KCl, 10 mM DTT [pH 7.5]) and 10 μM ZnSO4, 1 μl of 50% glycerol, 1 μg/μl pol
y(deoxyinosinic-deoxycytidylic) acid, 5 mmol/L MgCl2 and 1% Nonidet P-40 at room temperature for 20 min-
utes. The oligonucleotides and methylated oligonucleotides (eurofins) were annealed and used as probes or com-
petitors (Supplementary Table 2). All competitors were used at 200-fold excess. For supershift experiments, the 
nuclear extracts were incubated with 4 μg of anti-Kaiso Ab (6 F/6F8, ab12723; Abcam) and 5 μg of anti- HDAC3 
Ab (ab7030; Abcam). The binding mixtures were loaded onto 6% native acrylamide gel (Thermo Fisher Scientific) 
in Tris/borate/EDTA buffer and electrophoresed for 50 minutes at room temperature under a constant 100 V. The 
gels were then transferred to a nylon membrane at 4 °C for 50 minutes under a constant 100V and exposed to UV 
light to crosslink for 15 minutes. The DNA binding activity was detected using a LightShift chemiluminescent 
EMSA kit (Thermo Fisher Scientific). The image was obtained using an LAS-3000 IR.
Construction of reporter plasmids. The Kaiso regulatory region in Ctse gene was amplified from B6 or 
MRL mice genomic DNAs isolated from splenic CD4+ T cells by using 5′-primer with XhoI restriction site 
(5′-GGGGGGCTCGAGGGACATCCTTCTAGGAAGCG-3′), and 3′-primer with HindIII restriction site 
(5′-GGGGGGAAGCTTGGTGTGTGTGTGTCTGATACTG-3′), and TaKaRa Taq Hot Start Version. The 
PU.1 promoter region17 in Ctse gene was amplified with 5′-primer with KpnI site (5′-GGGGGGGTACC 
GGACCCTCATTCACTTTTGC-3′) and 3′-primer with XhoI site (5′-GGGGGCTCGAGGAGACAGGGCC 
TTACCTGTG-3′). The PCR products of Kaiso regulatory region and PU.1 promoter region were ligated to multiple 
cloning site of the pGL4.10 [luc2] Vector (Promega)(Supplementary Fig. 2).
Plasmids were transformed in TOP10 (Invitrogen) expressing Dam and Dcm methylases, which methylate 
GATC in the former, and CCAGG and CCTGG in the latter. Thus, CGCG and CGGG sites were not methylated 
in TOP10 competent cells. Twenty micrograms of plasmids were methylated using 16 U of CpG methyltrans-
ferase (M. SssI) and S-adenosyl methionine (SAM: New England Biolabs) at 37 °C for 16 hours, with subsequent 
inactivation of enzyme at 65 °C for 20 minutes. Mock-methylation reactions were also performed in the absence 
of M. SssI and SAM. The methylated or mock-methylated constructs were purified using EndoFree Plasmid Maxi 
Kit (Qiagen) and the methylation status of each construct was determined by methylation-sensitive restriction 
enzyme AccII (TaKaRa) for plasmid constructs and empty vector.
Cell transfection. The transfection of plasmids into EL4 cells was performed using Neon electroporation 
system (Thermo Fisher Scientific) in serum-free medium with one pulse with a voltage of 1080 Volts and width 
of 50 ms. pGL4.10 [luc2] derived constructs (Supplementary Fig. 2). Following the transfection, 2 × 105 EL4 cells 
were cultured in 24-well plates and harvested after 24-hour incubation. Cytoplasmic extracts were prepared using 
a luciferase assay kit (Promega) in accordance with the manufacturer’s instructions.
statistical analyses. All results are shown as the mean ± standard deviation (SD) of data from at least three 
separate experiments, each performed with more than triplicate samples. The differences between the groups 
were analyzed using ANOVA with a Tukey–Kramer post hoc test or an unpaired t test, when appropriate, to 
determine the differences. P values less than 0.05 were considered significant. All statistical analyses were per-
formed using the JMP 11.2.0 software package (SAS Institute).
ethical approval and informed consent. The experiments were approved by the Animal Care and Use 
Committee of the Department of Animal Resources, Advanced Science Research Center, Okayama University 
(OKU-2015569 and OKU-2013092). All animal experiments were performed in accordance with relevant guide-
line and regulations.
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